	Incremental prognostic value of immune cell densities beyond clinical parameters in non-small cell lung cancer. Lung Cancer Nordling L, Backman M, Mezheyeuski A, Lindblad J, Sladoje N, Micke P. PMID: 41671623 [PubMed - as supplied by publisher]
	Evaluation of the ALIBIRD mHealth Platform for Care of Patients With Lung Cancer: Prospective Pilot Study. JMIR Cancer Iniesta-Chamorro JM, Sereno M, Garrido-Rubiales B, Villarino Sanz M, Espinosa-Salinas I, Falagán Martínez S, Rubio Romero G, Moreno-Rubio J, Tabarés B, Martín Y, Hernández de Córdoba I, Morales Parga M, Molinero N, Moreno-Arribas MV, Reglero Rada G, Ramírez de Molina A, Gómez EJ, Casado E. PMID: 41671557 [PubMed - indexed for MEDLINE]
	Health Beliefs and Adherence to Lung Cancer Screening in a Diverse Safety-Net Population. J Natl Compr Canc Netw Bhalla S, Hamann HA, Prasad T, Mullins MA, Malone ST, Rodriguez J, Gwin ME, Natchimuthu V, Nair RG, Ibekwe-Agunanna LN, Craddock Lee SJ, Johnson DH, Wahid U, Gao A, Zhang S, Gerber DE. PMID: 41671468 [PubMed - indexed for MEDLINE]
	NCCN GuidelinesÂ® Insights: Small Cell Lung Cancer, Version 2.2026. J Natl Compr Canc Netw Ganti AKP, Loo BW Jr, Badiyan S, Bassetti M, Bestvina C, Chiang A, Choudhury N, D'Avella CA, Daly M, Dowlati A, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Khalil M, Lee R, Malhotra J, Merritt RE, Mohindra N, Molina JR, Moran C, Mulvey C, Osmundson EC, Patel S, Patil T, Pokharel S, Puri S, Qin A, Sands J, Shields M, Tailor TD, Waqar SN, Cassara CJ, Ramakrishnan S. PMID: 41671459 [PubMed - indexed for MEDLINE]
	Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study. J Natl Compr Canc Netw Waliany S, Roy SG, Pecci F, Weber UM, Sun F, Arter Z, Lomibao M, Alessi JV, Nishino M, Luo F, Repetto M, Falcon C, Do A, Peterson J, Liang J, Liu A, Nagasaka M, Ricciuti B, Drilon A, Ou SI, Neal JW, Patil T, Awad M, Yeap BY, Digumarthy SR, Lin JJ. PMID: 41671458 [PubMed - indexed for MEDLINE]
	From Diagnosis, Therapy Decision-Making to Genetic Risk Assessment: The Impact of ctDNA Testing on Comprehensive Cancer Management-A Case Report. J Natl Compr Canc Netw Kanwar N, Seyi AB, Tan N, Rojas C, Ernani V, Rumilla KM, Borad MJ, Zheng G. PMID: 41671451 [PubMed - indexed for MEDLINE]
	Identifying regulatory driver motifs in non-small cell lung carcinoma via a systematic approach. PLoS One Kumar R, Massey S, Albogami S, Aloliqi AA, Asiri A, Aljohani MM, Aljohani HM, Kumar A, Dev K. PMID: 41671297 [PubMed - indexed for MEDLINE]
	Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study. Clin Cancer Res Chen M, Bulat I, Maglakelidze M, Li N, Chen Z, Kong W, Li Y, Fang J, Zhang J, Zhang J, Wang B, Ma J, Sun Y, Wang Q, Chen X, Liu X, Yu T, Hanley WD, Budha N, Li H, Lin X, Niu Z, Jamal L, Abdrashitov R, Wang M. PMID: 41671081 [PubMed - as supplied by publisher]
	Genomic alterations and their correlation with metabolic-related genes in lung cancer. Clin Transl Oncol Gaur G, Jha NK, Gambhir L, Acharya SV, Kumar D. PMID: 41670818 [PubMed - as supplied by publisher]
	Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase-driven non-small cell lung cancer therapy. Naunyn Schmiedebergs Arch Pharmacol Gumma L, Gumma B, Yarrabothula LP. PMID: 41670693 [PubMed - as supplied by publisher]
	T-Cell Immunity and Lung Cancer. Respirology Yamada K, Togashi Y. PMID: 41669970 [PubMed - as supplied by publisher]
	Single cell atlas of the comorbidity mechanism between chronic obstructive pulmonary disease and lung adenocarcinoma: a study of multi-omics combined analysis. PeerJ Li M, Wang B, Peng Q, Shen W, Shi D, Li X, Yu D, Li Y. PMID: 41669548 [PubMed - indexed for MEDLINE]
	The impact of radioligand therapy on prognosis in patients with lung neuroendocrine tumors. Front Endocrinol (Lausanne) Jó, Saracyn M, Durma AD, Ko, M, Dziuk M, Janiak K, Balcerska Z, Gniadek-Olejniczak K, Kami. PMID: 41669545 [PubMed - indexed for MEDLINE]
	Temporal evolution of CT imaging features in oligometastatic lung lesions after stereotactic body radiation therapy: a multicenter retrospective study of early tumor response as a predictor of favorable local control. Quant Imaging Med Surg He W, Yu H, Zhou C, Jiang Y, Pang J, Wang S, Bu L, Lu Z, Pan H, Yan S, Zhao F. PMID: 41669475 [PubMed]
	Enhancing cancer prognostics with group penalty models: a comparative study on radiomics feature selection in lung adenocarcinomas and meningiomas. Quant Imaging Med Surg Kwon Y, Suh YJ, Park YW, Ahn SS, Han K, Ha MJ. PMID: 41669447 [PubMed]
	Diagnostic dilemma of a large pulmonary mass: tuberculosis mimicking lung cancer with pre-malignant lesions. Quant Imaging Med Surg Gao W, Liu X, Wang T, Guo Y, Yin C, Xu H, Zeng Y. PMID: 41669436 [PubMed]
	Inpatient burden of lung cancer and changes after a hospital performance reform: a real-world study. Front Oncol Han B, Chen X. PMID: 41669262 [PubMed]
	TROPION-Lung10: a phase 3 study of datopotamab deruxtecan and rilvegostomig in patients with treatment-naÃ¯ve locally advanced or metastatic nonsquamous non-small cell lung cancer with high PD-L1 expression and without actionable genomic alterations. Front Oncol Newsom-Davis T, Melosky B, Heist RS, Lu S, Pasello G, Chen X, Stachowiak M, Lyfar P, Forcina A, Ramalingam SS. PMID: 41669261 [PubMed]
	Residual-SwishNet: a deep learning-based approach for reliable lung cancer classification. Front Oncol Nawaz M, Javed A, Saudagar AKJ. PMID: 41669256 [PubMed]
	Therapeutic strategies for KRAS G12C-mutant non-small cell lung cancer: from bench to bedside and beyond. Front Pharmacol Huang R, Gong X, Du J, Xu G, Qian J, Liao G, Lin Y, Pan M, Zheng B, Yuan W, Huang Q, Chen C, Yang Z. PMID: 41668807 [PubMed]

Articles 1 - 20 / 156276

Page 1 of 7814



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy